FRAMINGHAM (09/24/2003) - Last month, ArQule Inc. was set to acquire Cyclis Pharmaceuticals Inc., a privately held cancer therapeutics company. In addition to US$25 million in cash and common stock, ArQule will assume all of the outstanding debt and liabilities of Cyclis, which are estimated to range between $5 million and $6 million. ArQule believes that Cyclis' approach, Activated Checkpoint Therapy (ACT), has the potential for improved activity and reduced toxicity over other molecular approaches and traditional cancer chemotherapy. Cyclis' lead compound, CO-501, is expected to enter Phase I clinical trials in 2003.
- Free Whitepaper! The 5 criteria to help you select the right analytics platform for your organization.
- Free Whitepaper! Learn how IT is evolving from producer to enabler, and fostering collaboration around analytics.
- Free Whitepaper! Learn how to create an analytics environment that is governed, scalable and self-serve.